Andrea Mokler-Mayer
Tuebingen, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.
Journal: Nature medicine
Published: June 19, 2026
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.
Journal: Nature medicine
Published: August 05, 2024
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.
Journal: Journal for immunotherapy of cancer
Published: June 21, 2024
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 14, 2021
IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Journal: Human vaccines & immunotherapeutics
Published: January 28, 2015
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
Journal: Nature medicine
Published: February 28, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026